Metraipolis › archive › dc_d2e72899ee6f

Insulin Glargine Biosimilar Prescribing and Cost Trends in the United Kingdom's Primary Care from 2020 to 2024 — Europe PMC PMID:40560030

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/40560030
DOI
10.3390/pharmacy13030085
License (as archived)
solo-consultazione
Archived
2026-10-08T03:26:35.063Z
SHA-256 of the archived text
08cb93d2676a0799211d254b96bdba66a65e900e22b901491ca8833e68da35c0
Stable URL of this page
https://metraipolis.com/documento/dc_d2e72899ee6f

How to cite

Insulin Glargine Biosimilar Prescribing and Cost Trends in the United Kingdom's Primary Care from 2020 to 2024 — Europe PMC PMID:40560030 — Europe PMC (en), https://europepmc.org/article/MED/40560030 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_d2e72899ee6f (Metraipolis archive dc_d2e72899ee6f, sha256 08cb93d2676a0799211d254b96bdba66a65e900e22b901491ca8833e68da35c0)
BibTeX
@misc{dcd2e72899ee6f,
  title = {Insulin Glargine Biosimilar Prescribing and Cost Trends in the United Kingdom's Primary Care from 2020 to 2024 — Europe PMC PMID:40560030},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/40560030},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_d2e72899ee6f; sha256 08cb93d2676a0799211d254b96bdba66a65e900e22b901491ca8833e68da35c0},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/40560030. Agents can read the archived copy with the MCP tool read_document.